Targeted Therapy Shrinks Rare Cancer, Opens Door to Transplant
Keaton Herzer, diagnosed with cholangiocarcinoma, was told he’d remain in lifelong treatment, but a newer targeted therapy shrank his tumors enough to qualify for a liver transplant. Post‑transplant, doctors see no signs of cancer, offering new hope and reshaping his outlook and that of others facing similar diagnoses.